15 December 2021 - - COVID-19 RT-PCR saliva tests using the Spectrum SDNA-1000 for bio-sample collection will also successfully be able to detect the additional Omicron viral variant and its mutations, US-based life science medical device manufacturing company Spectrum Solutions, LLC said.

Initially identified in South Africa, this variant has swiftly spread into Europe and is now being detected in North America. The Omicron variant (B.1.1.529) currently contains approximately 30 different mutations.

Spectrum's SNDA-1000 is a saliva collection technology promising a more accurate, noninvasive, and safer viral testing solution.

The company said it was the first saliva collection device to be EUA authorized by the FDA for saliva-based PCR COVID-19 testing as well as direct-to-patient at-home testing applications that include unsupervised sample self-collection.

The FDA validation of this all-in-one, patented sample collection, preservation, and transport system highlights the device's ability to neutralize the live virus at ambient temperatures further mitigating downstream risks of exposure and spread.

Headquartered in Salt Lake City, Utah, Spectrum Solutions is a life science medical device manufacturing company offering bio-sample collection devices, patented technologies, and dedicated services.